Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Overview
Explore Rapport Therapeutics, Inc. Common Stock’s financial performance, market position, analyst ratings, and future outlook.
Rapport Therapeutics, Inc. Common Stock (RAPP)
Key Financials
Key Financials
Market Cap
2B
P/E Ratio
-16.23
EPS (TTM)
$-2.60
ROE
-0.25%
RAPP Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Rapport Therapeutics, Inc. Common Stock (NASDAQ: RAPP) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Rapport Therapeutics, Inc. Common Stock's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of RAPP on the NASDAQ shows an RSI of 54.12, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $42.29 for the NASDAQ listing.
Key metrics behind Rapport Therapeutics, Inc. Common Stock's NASDAQ-traded stock include a P/E ratio of -16.23 and a market capitalization of 2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RAPP on the NASDAQ.